Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/26019
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Snelson, Matthew | - |
dc.contributor.author | de Pasquale, Cassandra | - |
dc.contributor.author | Ekinci, Elif I | - |
dc.contributor.author | Coughlan, Melinda T | - |
dc.date | 2021-02-17 | - |
dc.date.accessioned | 2021-03-09T05:05:10Z | - |
dc.date.available | 2021-03-09T05:05:10Z | - |
dc.date.issued | 2021-05 | - |
dc.identifier.citation | Best Practice & Research. Clinical Endocrinology & Metabolism 2021; 35(3): 101507 | en |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/26019 | - |
dc.description.abstract | Diabetes is a metabolic condition. The composition of the gut microbiota is altered in diabetes with reduced levels of short chain fatty acids (SCFA) producers, notably butyrate. Butyrate is associated with a number of beneficial effects including promoting the integrity of the gastrointestinal barrier. Diabetes may lead to an increase in the permeability of the gut barrier, which is thought to contribute to systemic inflammation and worsen the microvascular complications of diabetes. Prebiotics, non-digestible carbohydrates, are fermented by the colonic microbiota leading to the production of a range of metabolites including SCFAs. Thus, prebiotics represent a dietary approach to increase levels of microbially produced SCFAs and improve intestinal permeability in diabetes. Whether prebiotics can lead to a reduction in the risk of developing diabetes complications in individuals with type 2 diabetes needs to be explored. | en |
dc.language.iso | eng | - |
dc.subject | diabetes | en |
dc.subject | diabetic kidney disease | en |
dc.subject | intestinal permeability | en |
dc.subject | prebiotics | en |
dc.subject | short chain fatty acids | en |
dc.title | Gut microbiome, prebiotics, intestinal permeability and diabetes complications. | en |
dc.type | Journal Article | en |
dc.identifier.journaltitle | Best Practice & Research. Clinical Endocrinology & Metabolism | en |
dc.identifier.affiliation | Department of Diabetes, Central Clinical School, Alfred Medical Research and Education Precinct, Monash University, Melbourne, Victoria, Australia | en |
dc.identifier.affiliation | Department of Diabetes, Central Clinical School, Alfred Medical Research and Education Precinct, Monash University, Melbourne, Victoria, Australia | en |
dc.identifier.affiliation | Baker Heart and Diabetes Institute, Melbourne, Australia | en |
dc.identifier.affiliation | Endocrinology | en |
dc.identifier.affiliation | Medicine (University of Melbourne) | en |
dc.identifier.doi | 10.1016/j.beem.2021.101507 | en |
dc.type.content | Text | en |
dc.identifier.pubmedid | 33642218 | - |
local.name.researcher | Ekinci, Elif I | |
item.fulltext | No Fulltext | - |
item.openairetype | Journal Article | - |
item.cerifentitytype | Publications | - |
item.grantfulltext | none | - |
item.languageiso639-1 | en | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
crisitem.author.dept | Endocrinology | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.